NASDAQ:GENE

Genetic Technologies (GENE) Stock Forecast, Price & News

$0.96

-0.01 (-1.26%)

(As of 05:16 PM ET)

Compare

Today's Range: $0.95
▼
$0.98
50-Day Range: $0.93
▼
$1.19
52-Week Range: $0.83
▼
$2.40

Volume: 23,849 shs
Average Volume: 1.41 million shs
Market Capitalization: $18.43 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

About Genetic Technologies (NASDAQ:GENE) Stock

Genetic Technologies Ltd. is a molecular diagnostics company, which engages in the provision of molecular risk assessment tests for cancer. It operates through EasyDNA and GeneType/Corporate segments. The EasyDNA segment focuses on EasyDNA branded test sales and expenses. The GeneType/Corporate segment includes tha GeneType branded test sales and expenses, including corporate charges. The company was founded on January 5, 1987 and is headquartered in Fitzroy, Australia.

Receive GENE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Genetic Technologies and its competitors with MarketBeat's FREE daily newsletter.

GENE Stock News Headlines

May 23, 2023 | finance.yahoo.com

GeneType featured on U.S. National TV to raise Breast Cancer Awareness

May 4, 2023 | msn.com

'Genetic Havoc' - Five Reasons to Be Concerned About Gene-Edited Teff [analysis]

May 31, 2023 | Behind the Markets (Ad)

Small A.I. Firm Wins $2 Billion in Contracts for Breakthrough "Living Software"

Denver firm proves its possible to use AI to save the lives of soldiers in combat. England, Germany, Japan and Australia have all signed contracts within the past 18 months. Get the name of the stock here >>>

May 2, 2023 | benzinga.com

Genetic Technologies Stock (NASDAQ:GENE), Guidance and Forecast

May 1, 2023 | benzinga.com

Genetic Technologies Stock (NASDAQ:GENE), Dividends

April 23, 2023 | americanbankingnews.com

Genetic Technologies (NASDAQ:GENE) Shares Cross Above 200-Day Moving Average of $1.14

March 13, 2023 | finance.yahoo.com

Back-to-back Studies Validate geneType Breast Cancer Risk Test

March 9, 2023 | benzinga.com

Preimplantation Genetic Testing Market Value To Top Us$ 1.4 Billion By 2032 : Fact.MR Study

May 31, 2023 | Behind the Markets (Ad)

Small A.I. Firm Wins $2 Billion in Contracts for Breakthrough "Living Software"

February 27, 2023 | msn.com

Decoding genetic technologies

February 7, 2023 | finance.yahoo.com

Genetic Technologies Announces Closing of $5 Million Registered Direct Offering

February 6, 2023 | finance.yahoo.com

Genetic Technologies to Launch Ground-breaking Comprehensive Risk Test for Breast & Ovarian Cancer

February 3, 2023 | msn.com

Why Genetic Technologies Shares Are Skyrocketing During Premarket Session

February 3, 2023 | finance.yahoo.com

Genetic Technologies Announces $5 Million Registered Direct Offering

February 1, 2023 | marketwatch.com

Genetic Technologies Shares Rise 8% After Qiagen Partnership

February 1, 2023 | finance.yahoo.com

GTG to form Strategic Alliance with global testing leader QIAGEN

December 8, 2022 | msn.com

India says GM technology important for food security, import reduction

December 1, 2022 | finance.yahoo.com

Syncona Limited Portfolio Company Successfully Completes Tender Offer and Acquisition of Applied Genetic Technologies Corporation

November 29, 2022 | finance.yahoo.com

Syncona Limited Portfolio Company Extends Tender Offer to Acquire Applied Genetic Technologies Corporation

November 15, 2022 | benzinga.com

SHAREHOLDER ALERT: Weiss Law Investigates Applied Genetic Technologies Corporation

November 11, 2022 | wsj.com

‘As Gods’ Review: Genetic Technology’s Human Revolution

November 10, 2022 | finance.yahoo.com

Webinar - Dr Erika Spaeth to interview A/Prof Charles Siles on risk assessment tests for serious disease

November 9, 2022 | finance.yahoo.com

Genetype for Ovarian Cancer Published in Prestigious European Journal of Cancer Prevention

November 8, 2022 | benzinga.com

Sequencing.com Raises $5 Million In Venture Capital to Fund Groundbreaking DTC DNA Technology

October 27, 2022 | proactiveinvestors.com

Genetic Technologies’ breast screening tech 9x more sensitive than current screening

October 25, 2022 | benzinga.com

Genetic Technologies Announces Q1 FY23 Quarterly Results; Q1 Sales Of A$1.93M An Increase Of 375% From Q1 FY22

October 25, 2022 | finance.yahoo.com

Genetic Technologies Announces Q1 FY23 Quarterly Results and Investor Webinar Details

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive GENE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Genetic Technologies and its competitors with MarketBeat's FREE daily newsletter.

GENE Company Calendar

Today: 5/31/2023
Fiscal Year End: 6/30/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:GENE
CUSIP: N/A
CIK: 1166272
Web: www.gtgcorporate.com
Phone: (138) 412-7000
Fax: 011-61-3-8412-7040
Employees: 18
Year Founded: 1989

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: 0.03
Current Ratio: 2.08
Quick Ratio: 1.98

Sales & Book Value

Annual Sales: $4.86 million
Price / Sales: 3.79
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.77 per share
Price / Book: 1.24

Miscellaneous

Outstanding Shares: 19,240,000
Free Float: 17,993,000
Market Cap: $18.42 million
Optionable: Optionable
Beta: 1.58

Social Links

Key Executives

Simon Morriss
Chief Executive Officer

Tony di Pietro
Chief Financial Officer & Secretary

Richard Allman
Chief Scientific Officer

Erika Spaeth
Director-Clinical Affairs & Medical Education

Carl Stubbings
Chief Commercial Officer

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

GENE Stock - Frequently Asked Questions

How have GENE shares performed in 2023?: Genetic Technologies' stock was trading at $0.93 at the start of the year. Since then, GENE shares have increased by 2.9% and is now trading at $0.9572.
View the best growth stocks for 2023 here.
What other stocks do shareholders of Genetic Technologies own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Genetic Technologies investors own include Vascular Biogenics (VBLT), Caladrius Biosciences (CLBS), Inovio Pharmaceuticals (INO), Novavax (NVAX), OPKO Health (OPK), Sangamo Therapeutics (SGMO), Advanced Micro Devices (AMD), Atossa Therapeutics (ATOS), FuelCell Energy (FCEL) and Heat Biologics (HTBX).
What is Genetic Technologies' stock symbol?: Genetic Technologies trades on the NASDAQ under the ticker symbol "GENE."
Who are Genetic Technologies' major shareholders?: Genetic Technologies' stock is owned by many different retail and institutional investors. Top institutional shareholders include OLD Mission Capital LLC (0.11%).

How do I buy shares of Genetic Technologies?: Shares of GENE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Genetic Technologies' stock price today?: One share of GENE stock can currently be purchased for approximately $0.96.
How much money does Genetic Technologies make?: Genetic Technologies (NASDAQ:GENE) has a market capitalization of $18.42 million and generates $4.86 million in revenue each year.
How can I contact Genetic Technologies?: Genetic Technologies' mailing address is 60-66 HANOVER STREET, FITZROY C3, 3065. The official website for the company is www.gtgcorporate.com. The biotechnology company can be reached via phone at (138) 412-7000, via email at ir@gtgcorporate.com, or via fax at 011-61-3-8412-7040.

This page (NASDAQ:GENE) was last updated on 5/31/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial